Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Accumulated Expenses (2016 - 2017)

Amicus Therapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $5.4 million for Q4 2017.

  • For the quarter ending Q4 2017, Other Accumulated Expenses rose 136.03% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Dec 2017, up 136.03%, and an annual FY2017 reading of $5.4 million, up 136.03% over the prior year.
  • Other Accumulated Expenses for Q4 2017 was $5.4 million at Amicus Therapeutics, up from $2.3 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $5.4 million in Q4 2017, with the low at $275000.0 in Q4 2013.
  • Average Other Accumulated Expenses over 4 years is $1.7 million, with a median of $679500.0 recorded in 2014.
  • Year-over-year, Other Accumulated Expenses surged 51.1% in 2013 and then surged 164.73% in 2014.
  • Tracing FOLD's Other Accumulated Expenses over 4 years: stood at $275000.0 in 2013, then soared by 164.73% to $728000.0 in 2014, then skyrocketed by 214.56% to $2.3 million in 2016, then soared by 136.03% to $5.4 million in 2017.
  • Per Business Quant, the three most recent readings for FOLD's Other Accumulated Expenses are $5.4 million (Q4 2017), $2.3 million (Q4 2016), and $607000.0 (Q3 2016).